Pollock ML, Franklin BA, Balady GJ, et al. AHA science advisory. Resistance exercise in individuals with and without cardiovascular dis- ease: benefits, rationale, safety, and prescription: an advisory from the CommitteeonExercise,Rehabilitation,andPrevention,CouncilonClinical Cardiology, American Heart Association. Circulation. 2000;101:828 33. 459. Gondoni LA, Liuzzi A, Titon AM, et al. A simple tool to predict exer- cise capacity of obese patients with ischaemic heart disease. Heart. 2006;92:899 904. 460. Rankin SL, Briffa TG, Morton AR, et al. A specific activity questionnaire to measure the functional capacity of cardiac patients. Am J Cardiol. 1996;77:1220 3. 461. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-adminis- tered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol. 1989;64:651 4. 462. Morris CK, Myers J, Froelicher VF, et al. Nomogram based on metabolic equivalents and age for assessing aerobic exercise capacity in men. J Am Coll Cardiol. 1993;22:175 82. 463. Flaker GC, Warnica JW, Sacks FM, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentra- tions. Cholesterol and Recurrent Events CARE. Investigators. J Am Coll Cardiol. 1999;34:106 12. 464. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59:1102 6. 465. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumo- coccal polysaccharide vaccine for adults with immunocompromising con- ditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816 9. 466. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46:1 24. 467. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxy- genase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633 44. 468. Deleted in press. 